Advertisement
Advertisement
U.S. Markets close in 1 hr 14 mins
Advertisement
Advertisement
Advertisement
Advertisement

10x Genomics, Inc. (TXG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
146.85+11.80 (+8.74%)
As of 02:46PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close148.42
Open148.46
Bid146.90 x 800
Ask147.16 x 1000
Day's Range136.75 - 149.01
52 Week Range128.15 - 208.99
Volume535,337
Avg. Volume718,263
Market Cap15.971B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.41
Earnings DateFeb 15, 2022 - Feb 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est203.67
  • PR Newswire

    10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year

    10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that Chromium X has been named one of The Scientist's 2021 Top 10 Innovations, an annual list of newly released products that have the potential to generate the biggest impact on scientific research. This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.

  • Insider Monkey

    Top 10 Stock Picks of Wen Han Li’s Andar Capital

    In this article, we discuss the top 10 stock picks of Wen Han Li’s Andar Capital. If you want to skip our detailed analysis of these stocks, go directly to the Top 5 Stock Picks of Wen Han Li’s Andar Capital. Wen Han Li is the portfolio manager of Andar Capital, which is an investment […]

  • Motley Fool

    10x Genomics Stock: Bull vs. Bear

    Despite crushing the S&P 500 -- 180% to 63% -- since its September 2019 IPO, 10x Genomics' (NASDAQ: TXG) shares have only experienced 6% growth year to date. The company has rapidly become a cornerstone of biomedical research with its laboratory devices capable of profiling individual cells, but investors recently seem to have shrugged. Does the stock price just need a few quarters to catch up to its valuation?

Advertisement
Advertisement